- Home
- IDYA vs BBUC Comparison
IDYA vs BBUC Comparison
Compare IDYA & BBUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- BBUC
- Stock Information
- Founded
- IDYA 2015
- BBUC 2022
- Country
- IDYA United States
- BBUC United States
- Employees
- IDYA N/A
- BBUC N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- BBUC
- Sector
- IDYA Health Care
- BBUC
- Exchange
- IDYA Nasdaq
- BBUC Nasdaq
- Market Cap
- IDYA 1.9B
- BBUC 1.7B
- IPO Year
- IDYA 2019
- BBUC N/A
- Fundamental
- Price
- IDYA $21.23
- BBUC $30.31
- Analyst Decision
- IDYA Strong Buy
- BBUC
- Analyst Count
- IDYA 13
- BBUC 0
- Target Price
- IDYA $53.42
- BBUC N/A
- AVG Volume (30 Days)
- IDYA 1.1M
- BBUC 103.8K
- Earning Date
- IDYA 08-05-2025
- BBUC 01-01-0001
- Dividend Yield
- IDYA N/A
- BBUC 0.80%
- EPS Growth
- IDYA N/A
- BBUC N/A
- EPS
- IDYA N/A
- BBUC N/A
- Revenue
- IDYA $7,000,000.00
- BBUC $8,309,000,000.00
- Revenue This Year
- IDYA $101.20
- BBUC N/A
- Revenue Next Year
- IDYA $286.70
- BBUC N/A
- P/E Ratio
- IDYA N/A
- BBUC N/A
- Revenue Growth
- IDYA N/A
- BBUC 8.15
- 52 Week Low
- IDYA $13.45
- BBUC $19.65
- 52 Week High
- IDYA $44.42
- BBUC $31.43
- Technical
- Relative Strength Index (RSI)
- IDYA 62.23
- BBUC 61.62
- Support Level
- IDYA $21.08
- BBUC $29.86
- Resistance Level
- IDYA $22.37
- BBUC $31.39
- Average True Range (ATR)
- IDYA 0.92
- BBUC 0.79
- MACD
- IDYA -0.09
- BBUC 0.14
- Stochastic Oscillator
- IDYA 61.72
- BBUC 73.54
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares
Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a world-wide basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.